Published in Blood on September 12, 2007
RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01
Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J (2011) 2.17
Lipid-based nanotherapeutics for siRNA delivery. J Intern Med (2010) 2.15
Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc Natl Acad Sci U S A (2010) 1.70
Progress toward in vivo use of siRNAs-II. Mol Ther (2011) 1.60
RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med (2009) 1.59
The Business of RNAi Therapeutics in 2012. Mol Ther Nucleic Acids (2012) 1.01
Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur J Immunol (2011) 0.94
Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules. Mol Cell Proteomics (2010) 0.92
Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest (2013) 0.87
Leukotriene C4 induces migration of human monocyte-derived dendritic cells without loss of immunostimulatory function. Blood (2012) 0.83
Messenger RNA (mRNA) nanoparticle tumour vaccination. Nanoscale (2014) 0.83
Generation of functional CD8+ T cells by human dendritic cells expressing glypican-3 epitopes. J Exp Clin Cancer Res (2010) 0.81
Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex. Biomolecules (2014) 0.79
Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells. Cancer Immunol Immunother (2011) 0.78
A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen. PLoS One (2012) 0.76
Association between putative functional variants in the PSMB9 gene and risk of melanoma--re-analysis of published melanoma genome-wide association studies. Pigment Cell Melanoma Res (2013) 0.76
Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma. J Immunother Cancer (2016) 0.76
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg (2007) 1.96
Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol (2005) 1.88
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2008) 1.83
Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg (2011) 1.82
Novel anticancer compounds induce apoptosis in melanoma cells. Cell Cycle (2008) 1.76
The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Ann Surg Oncol (2012) 1.66
Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol (2006) 1.62
In vivo optical molecular imaging and analysis in mice using dorsal window chamber models applied to hypoxia, vasculature and fluorescent reporters. Nat Protoc (2011) 1.62
Pancreatic duct strictures: identifying risk of malignancy. Ann Surg Oncol (2004) 1.52
Pancreatic adenocarcinoma. J Natl Compr Canc Netw (2010) 1.52
Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. Ann Surg Oncol (2006) 1.47
Predicting disease progression after regional therapy for in-transit melanoma. JAMA Surg (2013) 1.44
Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.44
A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg (2009) 1.39
Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res (2012) 1.38
Melanoma. J Natl Compr Canc Netw (2009) 1.37
Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol (2008) 1.36
Intraoperative radiation therapy. J Clin Oncol (2007) 1.31
Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg (2003) 1.30
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys (2007) 1.28
Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys (2005) 1.28
Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg (2014) 1.26
Clear cell hidradenoma: a mimic of metastatic clear cell tumors. Arch Pathol Lab Med (2005) 1.26
Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res (2009) 1.26
NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw (2009) 1.24
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol (2006) 1.21
Optical imaging of tumor hypoxia dynamics. J Biomed Opt (2011) 1.16
Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg (2002) 1.15
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res (2008) 1.11
Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.10
Effect of pazopanib on tumor microenvironment and liposome delivery. Mol Cancer Ther (2010) 1.09
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther (2010) 1.08
Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery (2003) 1.08
Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol (2011) 1.07
Oncolytic polio virotherapy of cancer. Cancer (2014) 1.05
Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol (2009) 1.03
The Kraske procedure: a critical analysis of a surgical approach for mid-rectal lesions. J Surg Oncol (2006) 1.02
Workforce projections for hepato-pancreato-biliary surgery. J Am Coll Surg (2008) 1.02
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest (2013) 1.02
A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer (2009) 1.01
Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol (2009) 1.01
Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol (2012) 1.00
Extended resection for pancreatic adenocarcinoma. Oncologist (2007) 0.99
Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma. Ann Surg Oncol (2006) 0.99
Tumor cells upregulate normoxic HIF-1α in response to doxorubicin. Cancer Res (2013) 0.99
Comparison of outcomes and the use of multimodality therapy in young and elderly people undergoing surgical resection of pancreatic cancer. J Am Geriatr Soc (2011) 0.96
Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer. Ann Surg Oncol (2006) 0.95
Neoadjuvant therapy for pancreatic cancer: the Duke experience. Surg Oncol Clin N Am (2004) 0.94
Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur J Immunol (2011) 0.94
The role of local excision in invasive adenocarcinoma of the ampulla of Vater. J Gastrointest Oncol (2013) 0.94
Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2010) 0.93
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin Cancer Res (2006) 0.93
Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. Arch Surg (2005) 0.93
Defining the learning curve for team-based laparoscopic pancreaticoduodenectomy. Ann Surg Oncol (2014) 0.93
Quantitative mapping of hemodynamics in the lung, brain, and dorsal window chamber-grown tumors using a novel, automated algorithm. Microcirculation (2013) 0.92
Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity. J Surg Res (2004) 0.92
Incidence of benign disease in patients that underwent resection for presumed pancreatic cancer diagnosed by endoscopic ultrasonography (EUS) and fine-needle aspiration (FNA). J Gastrointest Surg (2010) 0.92
Soft tissue sarcoma. J Natl Compr Canc Netw (2007) 0.91
Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4. J Immunol (2004) 0.91
Melanoma. J Natl Compr Canc Netw (2012) 0.90
Pediatric melanoma: a single-institution experience of 150 patients. J Pediatr Surg (2009) 0.89
Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses. J Surg Res (2005) 0.89
Regional treatment strategies for in-transit melanoma metastasis. Surg Oncol Clin N Am (2011) 0.89
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. Mol Cancer Ther (2010) 0.89
A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol (2011) 0.89
Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiat Oncol (2013) 0.89
Enhanced dendritic cell antigen presentation in RNA-based immunotherapy. J Surg Res (2002) 0.89
CYLD inhibits melanoma growth and progression through suppression of the JNK/AP-1 and β1-integrin signaling pathways. J Invest Dermatol (2012) 0.88
Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer (2004) 0.88
Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngol Head Neck Surg (2011) 0.87
Enhancing melanoma treatment with resveratrol. J Surg Res (2010) 0.87
Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest (2013) 0.87
In vivo tumor targeting by a NGR-decorated micelle of a recombinant diblock copolypeptide. J Control Release (2011) 0.87
Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg (2004) 0.87
Pancreas-preserving duodenectomy in the management of duodenal familial adenomatous polyposis. J Gastrointest Surg (2002) 0.86
Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2005) 0.85
Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma. Clin Cancer Res (2012) 0.85
CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy. Surgery (2003) 0.85